To date there is limited data on the immune profile and outcomes of solid organ transplant recipients who encounter COVID-19 infection early post-transplant. Here we present a unique case where the kidney recipient's transplant surgery coincided with a positive SARS-CoV-2 test and the patient subsequently developed symptomatic COVID-19 perioperatively. We performed comprehensive immunological monitoring of cellular, proteomic, and serological changes during the first 4 critical months post-infection. We showed that continuation of basiliximab induction and maintenance of triple immunosuppression did not significantly impair the host's ability to mount a robust immune response against symptomatic COVID-19 infection diagnosed within the first week post-transplant.
Keywords: COVID-19; immune response; immunosuppressants; induction therapy; transplant.
Copyright © 2021 Sherwood, Nicholl, Fenninger, Wu, Wong, Benedicto, Cina, Wang, Pobran, De Marco, Márquez, Jassem, Sekirov, Morshed, Bardi, Sekhon, Keown, Kadatz and Lan.